Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.

Martine Schollhammer 1 Emilie Brenaut 1, 2 Nicole Menard-Andivot Michelle Pillette-Delarue Anne Zagnoli Monique Chassain-Le Lay Bruno Sassolas 3 Nicole Jouan Yves Le Ru Claire Abasq-Thomas 1, 2 Matthieu Greco Katell Penven Anne-Marie Roguedas-Contios 1, 4, 5 Dominique Dupré-Goetghebeur Caroline Gouedard Laurent Misery 1, 2 Grégoire Le Gal 6, 7, 8, *
* Auteur correspondant
1 Dermato - BREST - Service de dermatologie
2 LNB - Laboratoire de Neurosciences de Brest
3 DMIP - Brest - Département de Médecine Interne et Pneumologie [Brest]
4 EA2216 - Immunologie et Pathologie
5 LabEX IGO Immunothérapie Grand Ouest
6 CIC 1412 - BREST - Centre d'Investigation Clinique INSERM 1412
7 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
8 OHRI - Ottawa Hospital Research Institute [Ottawa]
Abstract : Hyperhidrosis is a disorder that can impair quality of life. Localized treatments may be cumbersome and ineffective, and no systemic treatments have proven to be significantly beneficial. To evaluate the effectiveness and tolerance of low-dose oxybutynin for hyperhidrosis. We conducted a prospective, randomized, placebo-controlled trial. From June 2013 to January 2014, 62 patients with localized or generalized hyperhidrosis were enrolled. Oxybutynin was started at a dose of 2·5 mg per day and increased gradually to 7·5 mg per day. The primary outcome was defined as improvement of at least one point on the Hyperhidrosis Disease Severity Scale (HDSS). Dermatology Life Quality Index (DLQI) and tolerance were also reported. Most patients (83%) in our study had generalized hyperhidrosis. Oxybutynin was superior to placebo in improving the HDSS: 60% of patients treated with oxybutynin, compared with 27% of patients treated with placebo, improved at least one point on the HDSS (P = 0·009). The mean improvement in quality of life measured by DLQI was significantly better in the oxybutynin arm (6·9) than in the placebo arm (2·3). The most frequent side-effect was dry mouth, which was observed in 43% of the patients in the oxybutynin arm, compared with 11% in the placebo arm. Treatment with low-dose oxybutynin is effective in reducing symptoms of hyperhidrosis in generalized or localized forms. Side-effects were frequent but minor and mainly involved dry mouth.
Keywords : hyperhidrosis Oxybutynin
Type de document :
Article dans une revue
British Journal of Dermatology, Wiley, 2015, 173 (5), pp.1163-8. 〈10.1111/bjd.13973〉
Liste complète des métadonnées
http://hal.univ-brest.fr/hal-01276268
Contributeur : Ghislaine Calvez <>
Soumis le : vendredi 19 février 2016 - 10:16:49
Dernière modification le : mercredi 10 janvier 2018 - 14:42:02

Lien texte intégral

istex

Identifiants

Collections

UNIV-BREST | GETBO | IMMUNO | LIEN

Citation

Martine Schollhammer, Emilie Brenaut, Nicole Menard-Andivot, Michelle Pillette-Delarue, Anne Zagnoli, et al.. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.. British Journal of Dermatology, Wiley, 2015, 173 (5), pp.1163-8. 〈10.1111/bjd.13973〉. 〈hal-01276268〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

69

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD